SCHEMBL3757690

SCHEMBL3757690

CC(NC(=O)C1c2cc(F)ccc2C(=O)N1C(C)c1ccccc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.53
NPC1 O15118 1/20 0.43
MTOR P42345 1/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
TSHR P16473 2/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 1/20 0.40
AADAT Q8N5Z0 1/20 0.40
CACNA1G O43497 1/20 0.39
GPR139 Q6DWJ6 1/20 0.39
ACKR3 P25106 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3752007 0.89 KCNA5 (0.55) KCNA5TSHRHTTL3MBTL1
SCHEMBL3750904 0.86 KCNA5 (0.69) KCNA5RECQLTSHRHTTL3MBTL1
SCHEMBL3760228 0.86 KCNA5 (0.53) KCNA5TSHRHTTL3MBTL1
SCHEMBL3754015 0.84 KCNA5 (0.77) KCNA5TSHRGAAALDH1A1
SCHEMBL3752070 0.81 KCNA5 (0.48) KCNA5NPC1MTORCYP3A4CYP2D6
SCHEMBL3750647 0.80 KCNA5 (0.54) KCNA5TSHRHTTL3MBTL1
SCHEMBL3756535 0.78 KCNA5 (0.64) KCNA5CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL3750314 0.76 KCNA5 (0.48) KCNA5TSHRHTTL3MBTL1
SCHEMBL3749096 0.76 KCNA5 (0.55) KCNA5TSHRHTTL3MBTL1GPR139
SCHEMBL3760166 0.74 KCNA5 (0.48) KCNA5TSHRHTTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885NPC1 790/4885MTOR 4569/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885NPC1 1060/4885MTOR 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.